TGTX Stock Overview
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
TG Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.20|
|52 Week High||US$20.69|
|52 Week Low||US$3.48|
|1 Month Change||46.17%|
|3 Month Change||13.73%|
|1 Year Change||-50.87%|
|3 Year Change||-12.72%|
|5 Year Change||-0.61%|
|Change since IPO||621.67%|
Recent News & Updates
Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its DebtSep 07
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?Jun 06
Rock star Growth Puts TG Therapeutics (NASDAQ:TGTX) In A Position To Use DebtOct 25
Is TG Therapeutics (NASDAQ:TGTX) Using Too Much Debt?Jul 13
When Will TG Therapeutics, Inc. (NASDAQ:TGTX) Breakeven?Apr 19
Have Insiders Been Selling TG Therapeutics, Inc. (NASDAQ:TGTX) Shares?Feb 23
Do Insiders Own Lots Of Shares In TG Therapeutics, Inc. (NASDAQ:TGTX)?Jan 19
TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Slashed Next Year's Revenue Estimates By 12%Dec 14
How Much Are TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Taking Off The Table?Nov 24
|TGTX||US Biotechs||US Market|
Return vs Industry: TGTX underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: TGTX underperformed the US Market which returned -21.2% over the past year.
|TGTX Average Weekly Movement||21.7%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: TGTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: TGTX's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics, Inc. Fundamentals Summary
|TGTX fundamental statistics|
Is TGTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TGTX income statement (TTM)|
|Cost of Revenue||US$472.00k|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.78|
|Net Profit Margin||-4,748.89%|
How did TGTX perform over the long term?See historical performance and comparison